Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size was valued at US$ 750.3 million in 2023. With growing demand in downstream market, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is forecast to a readjusted size of US$ 1098.9 million by 2030 with a CAGR of 5.6% during review period.
The research report highlights the growth potential of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. It may include historical data, market segmentation by Type (e.g., Single-stranded AAV (ssAAV), Self-complementary AAV (scAAV)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy industry. This include advancements in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy technology, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy new entrants, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy new investment, and other innovations that are shaping the future of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. It includes factors influencing customer ' purchasing decisions, preferences for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.
Market Segmentation:
Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size was valued at US$ 750.3 million in 2023. With growing demand in downstream market, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is forecast to a readjusted size of US$ 1098.9 million by 2030 with a CAGR of 5.6% during review period.
The research report highlights the growth potential of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. It may include historical data, market segmentation by Type (e.g., Single-stranded AAV (ssAAV), Self-complementary AAV (scAAV)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy industry. This include advancements in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy technology, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy new entrants, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy new investment, and other innovations that are shaping the future of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. It includes factors influencing customer ' purchasing decisions, preferences for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market.
Market Segmentation:
Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Single-stranded AAV (ssAAV)
- Self-complementary AAV (scAAV)
- Hemophilia
- Ophthalmology
- Lysosomal Storage Disorders
- Neurological Disorders
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- BioMarin Pharmaceutical
- Sangamo Therapeutics
- Amicus Therapeutics
- Roche
- Pfizer
- NightstaRx
- MeiraGTx
- Sarepta Therapeutics
- Neurocrine Biosciences
- Voyager Therapeutics
- Asklepios Biopharmaceutical
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2030
2.1.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type
2.2.1 Single-stranded AAV (ssAAV)
2.2.2 Self-complementary AAV (scAAV)
2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
2.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application
2.4.1 Hemophilia
2.4.2 Ophthalmology
2.4.3 Lysosomal Storage Disorders
2.4.4 Neurological Disorders
2.4.5 Others
2.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
2.5.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
3 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SIZE BY PLAYER
3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Players
3.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2019-2024)
3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BY REGIONS
4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions (2019-2024)
4.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2019-2024)
4.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2019-2024)
4.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2019-2024)
4.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2019-2024)
5.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024)
5.3 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2019-2024)
6.2 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024)
6.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country (2019-2024)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024)
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Region (2019-2024)
8.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET FORECAST
10.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2025-2030)
10.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2025-2030)
10.1.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.1.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.1.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.1.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Country (2025-2030)
10.2.1 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.2.2 Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.2.3 Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.2.4 Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2025-2030)
10.3.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.2 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.3 Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.4 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.5 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.6 Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Country (2025-2030)
10.4.1 Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.2 France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.3 UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.4 Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.5 Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2025-2030)
10.5.1 Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.2 South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.3 Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.4 Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.5 GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Type (2025-2030)
10.7 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 BioMarin Pharmaceutical
11.1.1 BioMarin Pharmaceutical Company Information
11.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 BioMarin Pharmaceutical Main Business Overview
11.1.5 BioMarin Pharmaceutical Latest Developments
11.2 Sangamo Therapeutics
11.2.1 Sangamo Therapeutics Company Information
11.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Sangamo Therapeutics Main Business Overview
11.2.5 Sangamo Therapeutics Latest Developments
11.3 Amicus Therapeutics
11.3.1 Amicus Therapeutics Company Information
11.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Amicus Therapeutics Main Business Overview
11.3.5 Amicus Therapeutics Latest Developments
11.4 Roche
11.4.1 Roche Company Information
11.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Roche Main Business Overview
11.4.5 Roche Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 NightstaRx
11.6.1 NightstaRx Company Information
11.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 NightstaRx Main Business Overview
11.6.5 NightstaRx Latest Developments
11.7 MeiraGTx
11.7.1 MeiraGTx Company Information
11.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 MeiraGTx Main Business Overview
11.7.5 MeiraGTx Latest Developments
11.8 Sarepta Therapeutics
11.8.1 Sarepta Therapeutics Company Information
11.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Sarepta Therapeutics Main Business Overview
11.8.5 Sarepta Therapeutics Latest Developments
11.9 Neurocrine Biosciences
11.9.1 Neurocrine Biosciences Company Information
11.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Neurocrine Biosciences Main Business Overview
11.9.5 Neurocrine Biosciences Latest Developments
11.10 Voyager Therapeutics
11.10.1 Voyager Therapeutics Company Information
11.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Voyager Therapeutics Main Business Overview
11.10.5 Voyager Therapeutics Latest Developments
11.11 Asklepios Biopharmaceutical
11.11.1 Asklepios Biopharmaceutical Company Information
11.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Asklepios Biopharmaceutical Main Business Overview
11.11.5 Asklepios Biopharmaceutical Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2030
2.1.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type
2.2.1 Single-stranded AAV (ssAAV)
2.2.2 Self-complementary AAV (scAAV)
2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
2.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application
2.4.1 Hemophilia
2.4.2 Ophthalmology
2.4.3 Lysosomal Storage Disorders
2.4.4 Neurological Disorders
2.4.5 Others
2.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
2.5.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
3 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET SIZE BY PLAYER
3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Players
3.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2019-2024)
3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY BY REGIONS
4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions (2019-2024)
4.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2019-2024)
4.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2019-2024)
4.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2019-2024)
4.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2019-2024)
5.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024)
5.3 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2019-2024)
6.2 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024)
6.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country (2019-2024)
7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024)
7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Region (2019-2024)
8.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ADENO-ASSOCIATED VIRUS (AAV) VECTOR-BASED GENE THERAPY MARKET FORECAST
10.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2025-2030)
10.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Regions (2025-2030)
10.1.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.1.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.1.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.1.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast
10.2 Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Country (2025-2030)
10.2.1 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.2.2 Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.2.3 Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.2.4 Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3 APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2025-2030)
10.3.1 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.2 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.3 Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.4 Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.5 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.3.6 Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Country (2025-2030)
10.4.1 Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.2 France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.3 UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.4 Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.4.5 Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Region (2025-2030)
10.5.1 Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.2 South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.3 Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.4 Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.5.5 GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast
10.6 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Type (2025-2030)
10.7 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 BioMarin Pharmaceutical
11.1.1 BioMarin Pharmaceutical Company Information
11.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 BioMarin Pharmaceutical Main Business Overview
11.1.5 BioMarin Pharmaceutical Latest Developments
11.2 Sangamo Therapeutics
11.2.1 Sangamo Therapeutics Company Information
11.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Sangamo Therapeutics Main Business Overview
11.2.5 Sangamo Therapeutics Latest Developments
11.3 Amicus Therapeutics
11.3.1 Amicus Therapeutics Company Information
11.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Amicus Therapeutics Main Business Overview
11.3.5 Amicus Therapeutics Latest Developments
11.4 Roche
11.4.1 Roche Company Information
11.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Roche Main Business Overview
11.4.5 Roche Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 NightstaRx
11.6.1 NightstaRx Company Information
11.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 NightstaRx Main Business Overview
11.6.5 NightstaRx Latest Developments
11.7 MeiraGTx
11.7.1 MeiraGTx Company Information
11.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 MeiraGTx Main Business Overview
11.7.5 MeiraGTx Latest Developments
11.8 Sarepta Therapeutics
11.8.1 Sarepta Therapeutics Company Information
11.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Sarepta Therapeutics Main Business Overview
11.8.5 Sarepta Therapeutics Latest Developments
11.9 Neurocrine Biosciences
11.9.1 Neurocrine Biosciences Company Information
11.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Neurocrine Biosciences Main Business Overview
11.9.5 Neurocrine Biosciences Latest Developments
11.10 Voyager Therapeutics
11.10.1 Voyager Therapeutics Company Information
11.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Voyager Therapeutics Main Business Overview
11.10.5 Voyager Therapeutics Latest Developments
11.11 Asklepios Biopharmaceutical
11.11.1 Asklepios Biopharmaceutical Company Information
11.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Asklepios Biopharmaceutical Main Business Overview
11.11.5 Asklepios Biopharmaceutical Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Single-stranded AAV (ssAAV)
Table 3. Major Players of Self-complementary AAV (scAAV)
Table 4. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 7. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 10. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Player (2019-2024)
Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Products Offered
Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Regions (2019-2024)
Table 18. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country (2019-2024)
Table 22. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 24. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 26. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2019-2024)
Table 28. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 30. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 32. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country (2019-2024)
Table 34. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 36. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Table 45. Key Market Challenges & Risks of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Table 46. Key Industry Trends of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Table 47. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. BioMarin Pharmaceutical Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 52. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 53. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. BioMarin Pharmaceutical Main Business
Table 55. BioMarin Pharmaceutical Latest Developments
Table 56. Sangamo Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 57. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 58. Sangamo Therapeutics Main Business
Table 59. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. Sangamo Therapeutics Latest Developments
Table 61. Amicus Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 62. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 63. Amicus Therapeutics Main Business
Table 64. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. Amicus Therapeutics Latest Developments
Table 66. Roche Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 67. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 68. Roche Main Business
Table 69. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. Roche Latest Developments
Table 71. Pfizer Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 72. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 73. Pfizer Main Business
Table 74. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Pfizer Latest Developments
Table 76. NightstaRx Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 77. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 78. NightstaRx Main Business
Table 79. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 80. NightstaRx Latest Developments
Table 81. MeiraGTx Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 82. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 83. MeiraGTx Main Business
Table 84. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 85. MeiraGTx Latest Developments
Table 86. Sarepta Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 87. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 88. Sarepta Therapeutics Main Business
Table 89. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 90. Sarepta Therapeutics Latest Developments
Table 91. Neurocrine Biosciences Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 92. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 93. Neurocrine Biosciences Main Business
Table 94. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 95. Neurocrine Biosciences Latest Developments
Table 96. Voyager Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 97. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 98. Voyager Therapeutics Main Business
Table 99. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 100. Voyager Therapeutics Latest Developments
Table 101. Asklepios Biopharmaceutical Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 102. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 103. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. Asklepios Biopharmaceutical Main Business
Table 105. Asklepios Biopharmaceutical Latest Developments
Table 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Single-stranded AAV (ssAAV)
Table 3. Major Players of Self-complementary AAV (scAAV)
Table 4. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 7. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 10. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Player (2019-2024)
Table 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Products Offered
Table 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Regions (2019-2024)
Table 18. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country (2019-2024)
Table 22. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 24. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 26. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2019-2024)
Table 28. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 30. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 32. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country (2019-2024)
Table 34. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 36. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Table 45. Key Market Challenges & Risks of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Table 46. Key Industry Trends of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
Table 47. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. BioMarin Pharmaceutical Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 52. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 53. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. BioMarin Pharmaceutical Main Business
Table 55. BioMarin Pharmaceutical Latest Developments
Table 56. Sangamo Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 57. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 58. Sangamo Therapeutics Main Business
Table 59. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. Sangamo Therapeutics Latest Developments
Table 61. Amicus Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 62. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 63. Amicus Therapeutics Main Business
Table 64. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. Amicus Therapeutics Latest Developments
Table 66. Roche Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 67. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 68. Roche Main Business
Table 69. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. Roche Latest Developments
Table 71. Pfizer Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 72. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 73. Pfizer Main Business
Table 74. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Pfizer Latest Developments
Table 76. NightstaRx Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 77. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 78. NightstaRx Main Business
Table 79. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 80. NightstaRx Latest Developments
Table 81. MeiraGTx Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 82. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 83. MeiraGTx Main Business
Table 84. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 85. MeiraGTx Latest Developments
Table 86. Sarepta Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 87. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 88. Sarepta Therapeutics Main Business
Table 89. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 90. Sarepta Therapeutics Latest Developments
Table 91. Neurocrine Biosciences Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 92. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 93. Neurocrine Biosciences Main Business
Table 94. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 95. Neurocrine Biosciences Latest Developments
Table 96. Voyager Therapeutics Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 97. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 98. Voyager Therapeutics Main Business
Table 99. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 100. Voyager Therapeutics Latest Developments
Table 101. Asklepios Biopharmaceutical Details, Company Type, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Area Served and Its Competitors
Table 102. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Offered
Table 103. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. Asklepios Biopharmaceutical Main Business
Table 105. Asklepios Biopharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country/Region (2023)
Figure 8. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2023
Figure 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Hemophilia
Figure 11. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Hemophilia (2019-2024) & ($ Millions)
Figure 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Ophthalmology
Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Ophthalmology (2019-2024) & ($ Millions)
Figure 14. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Lysosomal Storage Disorders
Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Lysosomal Storage Disorders (2019-2024) & ($ Millions)
Figure 16. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Neurological Disorders
Figure 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Neurological Disorders (2019-2024) & ($ Millions)
Figure 18. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Others
Figure 19. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Others (2019-2024) & ($ Millions)
Figure 20. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2023
Figure 21. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Player in 2023
Figure 22. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Regions (2019-2024)
Figure 23. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2024 ($ Millions)
Figure 24. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2024 ($ Millions)
Figure 25. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2024 ($ Millions)
Figure 26. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2024 ($ Millions)
Figure 27. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Value Market Share by Country in 2023
Figure 28. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 29. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 30. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 31. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 32. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region in 2023
Figure 33. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2023
Figure 34. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2023
Figure 35. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 36. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 37. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 38. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 39. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 40. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 41. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country in 2023
Figure 42. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Figure 43. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Figure 44. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 45. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 46. UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 47. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 48. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 49. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2019-2024)
Figure 50. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Figure 51. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Figure 52. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 53. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 54. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 55. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 56. GCC Country Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 57. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 58. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 59. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 60. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 61. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 62. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 63. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 64. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 65. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 66. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 67. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 68. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 69. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 70. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 71. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 72. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 73. UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 74. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 75. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 76. Spain Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 77. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 78. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 79. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 80. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 81. GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 82. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Type (2025-2030)
Figure 83. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country/Region (2023)
Figure 8. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2023
Figure 10. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Hemophilia
Figure 11. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Hemophilia (2019-2024) & ($ Millions)
Figure 12. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Ophthalmology
Figure 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Ophthalmology (2019-2024) & ($ Millions)
Figure 14. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Lysosomal Storage Disorders
Figure 15. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Lysosomal Storage Disorders (2019-2024) & ($ Millions)
Figure 16. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Neurological Disorders
Figure 17. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Neurological Disorders (2019-2024) & ($ Millions)
Figure 18. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in Others
Figure 19. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Others (2019-2024) & ($ Millions)
Figure 20. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2023
Figure 21. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Player in 2023
Figure 22. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Regions (2019-2024)
Figure 23. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2024 ($ Millions)
Figure 24. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2024 ($ Millions)
Figure 25. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2024 ($ Millions)
Figure 26. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2019-2024 ($ Millions)
Figure 27. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Value Market Share by Country in 2023
Figure 28. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 29. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 30. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 31. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 32. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region in 2023
Figure 33. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2023
Figure 34. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2023
Figure 35. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 36. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 37. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 38. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 39. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 40. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 41. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Country in 2023
Figure 42. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Figure 43. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Figure 44. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 45. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 46. UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 47. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 48. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 49. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Region (2019-2024)
Figure 50. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
Figure 51. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application (2019-2024)
Figure 52. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 53. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 54. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 55. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 56. GCC Country Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth 2019-2024 ($ Millions)
Figure 57. Americas Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 58. APAC Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 59. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 60. Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 61. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 62. Canada Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 63. Mexico Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 64. Brazil Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 65. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 66. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 67. Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 68. Southeast Asia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 69. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 70. Australia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 71. Germany Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 72. France Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 73. UK Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 74. Italy Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 75. Russia Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 76. Spain Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 77. Egypt Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 78. South Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 79. Israel Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 80. Turkey Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 81. GCC Countries Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size 2025-2030 ($ Millions)
Figure 82. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Type (2025-2030)
Figure 83. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share Forecast by Application (2025-2030)
More Publications
Global Point-of-Care Testing (POCT) Devices Market Growth 2025-2031
US$ 3,660.00
January 2025
114 pages
Global Immunosuppressants API Market Growth 2024-2030
US$ 3,660.00
December 2024
117 pages
Global Breathing Exercise Machine Market Growth 2024-2030
US$ 3,660.00
March 2024
118 pages
Global Multifunctional Stretcher Market Growth 2024-2030
US$ 3,660.00
August 2024
115 pages
Global Biologics and Biosimilars Market Growth (Status and Outlook) 2026-2032
US$ 3,660.00
May 2026
121 pages
